--- title: "Collegium pays Grünenthal $17,000,000 to settle Nucynta suit and end license" url: "https://aibio.space/news/collegium-pays-grunenthal-17-000-000-settle-nucynta-suit-end-license/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-10-19" section: "Distress" tickers: "NASDAQ:COLL" source: "https://www.sec.gov/Archives/edgar/data/1267565/000110465926116876/tm2627827d1_8k.htm" summary: "Collegium will pay Grünenthal $17,000,000 to end a February 2026 patent suit and a Nucynta license that carried royalties. The 8-K does not say what those" --- By the aibio.space news desk. Sources - [Collegium Pharmaceutical, Inc. 8-K (2026-10-19)](https://www.sec.gov/Archives/edgar/data/1267565/000110465926116876/tm2627827d1_8k.htm) - [Collegium Pharmaceutical, Inc. 10-K (2026-02-26): business](https://www.sec.gov/Archives/edgar/data/1267565/000162828026011992/coll-20251231.htm) - [Collegium Pharmaceutical, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1267565/000162828026011992/) [COLL](https://aibio.space/companies/collegium-pharmaceutical/) 2026-10-19 # Collegium pays Grünenthal $17,000,000 to settle Nucynta suit and end license Tickers [COLL](https://aibio.space/companies/collegium-pharmaceutical/) Collegium will pay Grünenthal $17,000,000 to end a February 2026 patent suit and a Nucynta license that carried royalties. The 8-K does not say what those royalties cost the company. ## Key facts - **Company**: Collegium Pharmaceutical, Inc. (NASDAQ: COLL) - **News type**: Distress - **Primary source**: [Collegium Pharmaceutical, Inc. 8-K (2026-10-19)](https://www.sec.gov/Archives/edgar/data/1267565/000110465926116876/tm2627827d1_8k.htm) *A columned courthouse. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.* ## What was settled Collegium Pharmaceutical, Inc. (Nasdaq: [COLL](https://aibio.space/companies/collegium-pharmaceutical/)) said in a Form 8-K dated October 19, 2026 that it had settled with Grünenthal GmbH on October 15, 2026. The settlement resolves all disputes between the two companies, including a patent suit Grünenthal filed in February 2026 in the United States District Court for the District of New Jersey. The complaint named Collegium as the defendant and alleged patent infringement tied to the launch of an authorized generic of Nucynta ER. Collegium will pay Grünenthal $17,000,000. The parties ended the License Agreement (U.S.) dated January 13, 2015 in its entirety, and they ended the Consent Agreement dated January 30, 2020 for the Territory, a defined term in that agreement. The terminations took effect on October 15, 2026, after the payment. The rest of the Consent Agreement stays in force. The settlement also has Grünenthal assign certain patents related to the Nucynta products to Collegium and file a motion to dismiss the suit. The 8-K does not identify those patents, their expiry dates or whether any of them covers the authorized generic. The filing also does not say when the court will rule on the motion. ## Royalties ended, cost not given The 8-K says all royalty obligations under the license have been fully and finally discharged, and that no further royalties will be due. It does not give the royalty rate, the royalties Collegium paid in earlier years, or the value of the license that has now ended. It also does not say how the $17,000,000 payment will be recorded in the company's accounts. Collegium assumed the license through a Consent Agreement with Grünenthal and Assertio Therapeutics, Inc. as part of its 2020 acquisition of Nucynta ER and Nucynta IR. The 8-K describes the license and the agreement as previously disclosed and refers readers to copies filed with a quarterly report in May 2020. It does not restate their terms. ## The Nucynta franchise under generic pressure The annual report filed in February 2026 lists Nucynta ER and Nucynta IR among Collegium's marketed products, alongside JORNAY PM, Belbuca, Xtampza ER and Symproic. It says Collegium granted Hikma Pharmaceuticals USA Inc. rights to an authorized generic version of the Nucynta products in the United States. The annual report also describes competition that is already in the market. In January 2026, a third-party generic equivalent of Nucynta IR was approved under an abbreviated new drug application, with pediatric use carved out of its label. Hikma launched a generic version of Nucynta IR on February 25, 2026. Hikma was expected to launch a generic version of Nucynta ER in the first quarter of 2026. The annual report lists December 27, 2025 as the end of pediatric exclusivity for Nucynta ER and January 3, 2027 for Nucynta IR. The 8-K does not say who launched the authorized generic named in the suit, and it does not mention Hikma. ## Financial base Financial data from the company's filings show revenue of $780.6 million for 2025, up from $631.4 million for 2024. Net income fell to $62.9 million from $69.2 million. Cash provided by operations rose to $329.3 million from $205.0 million. Revenue grew while net income declined, and the cost of the Nucynta settlement comes on top of a franchise already losing exclusivity. The same data show cash and cash equivalents of $129.5 million at June 30, 2026, with no short-term investments at that date. The 8-K does not discuss the company's cash position. ## What comes next The 8-K does not say when the court will act on Grünenthal's motion to dismiss. The annual report lists January 3, 2027 as the end of pediatric exclusivity for Nucynta IR. The Consent Agreement stays in force outside the Territory, and the 8-K does not describe which obligations that leaves in place. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story COLL Collegium Pharmaceutical, Inc. NASDAQ · United States Open the starter desk ## More in Distress Distress ### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/) Oct 29, 2026 Distress ### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/) Oct 29, 2026 Distress ### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/) Oct 28, 2026 --- Source page: https://aibio.space/news/collegium-pays-grunenthal-17-000-000-settle-nucynta-suit-end-license/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Collegium pays Grünenthal $17,000,000 to settle Nucynta suit and end license", 2026-10-19, https://aibio.space/news/collegium-pays-grunenthal-17-000-000-settle-nucynta-suit-end-license/